Sanofi’s Principia Biopharma is taking a one-two punch. Just days after one of the subsidiary’s key BTK inhibitors crashed out of clinical testing, Sanofi has now disclosed it will wind down Principia’s San Francisco laboratories and lay off roughly three dozen employees in the process.

Medtronic is launching a pilot program to screen real-world data for people who may have a heightened risk of sudden cardiac arrest, with the goal of pairing them up with potentially life-saving hardware before a heart attack occurs.

Normally, chasing rainbows is an inherently futile act. Masimo’s pursuit, however, is the rare one proven fruitful, with a new CE mark for its Rainbow SuperSensor.

Before amyloid beta peptides can form the brain plaques that have been implicated in Alzheimer’s and other brain disorders, they have to bind to “fibrils,” protein aggregates that grow over time. But sometimes misaligned chemical forces prevent the peptides from locking onto fibrils—a failure that researchers now say could inspire new treatments.

Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia.

About four months after the abrupt exit of CEO Mike Coyle, a new leader is taking the helm at cardiac monitor maker iRhythm Technologies. Quentin Blackford will step into the dual role of CEO and president of the San Francisco-based company, effective Oct. 4. At that time, he’ll also join iRhythm’s board of directors.

Bellus Health needed a win for its chronic cough medicine BLU-5937 after dropping a previous round to Merck, and a new, planned interim analysis seems to have given the company what it needs to plan for phase 3.

Hoping to evolve new treatments across the board using B-cell therapies, Walking Fish Therapeutics has nabbed $50 million and a new chief in the form of an industry veteran.

After receiving approvals in brain cancer and mesothelioma for its tumor-treating electric fields, Novocure has secured a breakthrough designation from the FDA for the company’s devices aimed at aggressive liver cancer.

All ultrasound gels and lotions manufactured by Canada’s Eco-Med Pharmaceutical are at risk of having been contaminated by the bacteria Burkholderia cepacia (Bcc), the FDA determined, prompting the agency to issue a Class I recall alert covering almost all of the company’s products.